Status and phase
Conditions
Treatments
About
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Core Study Inclusion Criteria:
Male or female patients 18 years and older.
Patients within 7-42 days of an acute myocardial infarction associated with left ventricular systolic dysfunction.
Documented left ventricular systolic dysfunction associated with the qualifying acute myocardial.
Patients must be on stable doses of the following concomitant medications for at least 2 weeks prior to Visit 1 unless contraindicated due to intolerance:
Qualifying Echocardiogram at Visit 1:
Core Study Exclusion Criteria:
Extension Study Inclusion Criteria:
Extension Study Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied
Primary purpose
Allocation
Interventional model
Masking
820 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal